一种泛型肝炎E病毒复制抑制剂,在老鼠感染模型中具有高强度
Xin Zhang1, Mara Klöhn2, Sivi Ouwerkerk-Mahadevan3
1Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, KU Leuven, Leuven, Belgium.
Gastroenterology
|November 24, 2024
概括
一种新的抗病毒化合物,JNJ-9117,在治疗肝炎E病毒 (HEV) 感染方面表现有前途. 它有效地降低了老鼠的病毒载量,即使与利巴维林结合使用,并且具有良好的安全性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
背景情况:
- 肝炎E病毒 (HEV) 造成全球重大健康问题,每年有数百万人感染.
- 目前对HEV的治疗选择有限,特别是对于免疫功能低下的人和孕妇来说.
- 需要有效和安全的抗病毒疗法来对抗HEV.
研究的目的:
- 为了识别和评估新型抗病毒药物用于E型肝炎病毒 (HEV) 感染.
- 评估化合物JNJ-9117作为潜在的HEV治疗药物的疗效和安全性.
- 探索与现有的抗病毒药物结合治疗.
主要方法:
- 使用HEV亚基因组复制系统对核酸相似物进行选.
- 在各种细胞培养模型中进行体外抗病毒活性测试,包括初级人类肝细胞.
- 在已确立的慢性HEV感染的无血性裸体大鼠模型中进行了体内疗效评估.
主要成果:
- 化合物JNJ-9117在细胞培养中对多种HEV基因型表现出广泛的抗病毒活性.
- 这种药物在临床前小鼠研究中表现出有利的药理动力学和安全性.
- 在大鼠中,JNJ-9117显著降低了HEV RNA水平,与利巴维林结合时有效性提高.
结论:
- JNJ-9117显示出作为严重的肝炎E病毒感染的有前途的治疗剂的潜力.
- 该化合物的作用机制包括抑制病毒RNA合成.
- 一期人类临床试验已经开始,以评估JNJ-9117的安全性和耐受性.
相关概念视频
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...